Garren Hideki 4
4 · PROTHENA CORP PUBLIC LTD CO · Filed Jun 14, 2023
Insider Transaction Report
Form 4
Garren Hideki
Chief Medical Officer
Transactions
- Exercise/Conversion
Ordinary Shares, par value $0.01 per share
2023-06-14$24.90/sh+4,669$116,258→ 4,669 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-14$72.45/sh−509$36,879→ 4,160 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-14$73.31/sh−971$71,184→ 3,189 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-14$74.59/sh−2,534$189,010→ 655 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-14$75.49/sh−655$49,443→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-14−4,669→ 205,331 totalExercise: $24.90Exp: 2031-04-05→ Ordinary Shares (4,669 underlying)
Footnotes (6)
- [F1]The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.
- [F2]The transaction was executed in multiple trades in prices ranging from $71.96 to $72.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4.
- [F3]The transaction was executed in multiple trades in prices ranging from $73.03 to $73.995, inclusive.
- [F4]The transaction was executed in multiple trades in prices ranging from $74.16 to $75.13, inclusive.
- [F5]The transaction was executed in multiple trades in prices ranging from $75.26 to $76.20, inclusive.
- [F6]The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.